Barry Caldwell served as the President and CEO of Staar Surgical Company from November 2007 until his retirement in March 2015. His leadership was marked by his involvement in securing FDA approval for the company's ICLtm phakic implant, a significant...

Barry Caldwell served as the President and CEO of Staar Surgical Company from November 2007 until his retirement in March 2015. His leadership was marked by his involvement in securing FDA approval for the company's ICLtm phakic implant, a significant milestone for the business. In 2014, he decided to retire due to personal reasons, and after retirement, he continued on as a consultant until March 2016. He had a dynamic compensation structure during his time, with a peak salary of over $516,000 in 2014, but he did not earn a bonus that year as corporate goals weren’t met. Interestingly, during his tenure, he vested a substantial number of shares in restricted stock, including 45,000 shares worth approximately $669,000 in 2014 alone. Caldwell’s compensation package also included generous perks, such as relocation assistance and salary paid as stock, reflecting a strategic alignment with the company's growth. This combination of responsibilities and rewards showcases his long-term impact on the company’s direction and performance. He left a legacy of innovation and perseverance within Staar Surgical, laying the groundwork for its future success.

Quick Links

1. Rivals

2. Holdings

3. Insider Trading

4. Compensation History

5. Other Staar Surgical CEOs

S

Barry Caldwell

Ex-CEO of Staar Surgical

Sector of Economy

Healthcare

CEO of Staar Surgical for

7 years 4 months (Oct 2007 - Mar 2015)

Previous Experience

Unknown

Rivals

Competitors/colleagues of Barry Caldwell

Holdings

See how much did Barry Caldwell make over time.

Throughout his tenure at Staar Surgical, Barry Caldwell managed substantial stock holdings. He saw significant wealth fluctuations, especially considering he vested 45,000 shares valued at around $669,000 in 2014. At the peak of his tenure, Caldwell's stock portfolio comprised a...

Throughout his tenure at Staar Surgical, Barry Caldwell managed substantial stock holdings. He saw significant wealth fluctuations, especially considering he vested 45,000 shares valued at around $669,000 in 2014. At the peak of his tenure, Caldwell's stock portfolio comprised a considerable portion of his overall compensation, showcasing his financial stake in the company's success. Over time, his loyalty to Staar is reflected in the shares he owned, which influenced his wealth as the company's performance varied. After his retirement, his holdings were a critical part of his financial portfolio, especially as the company navigated market changes. This transition demonstrated Caldwell's shift from a leader striving for immediate results to a retiree focusing on the long-term performance of his investments with Staar Surgical.

Total Stock Sold

$82.50K

STAA

$82.50K

10,000 STAA shares

What if they kept their stock?

If Barry Caldwell didn't sell their stock, today they would have:
Extra STAA10,000 shares worth $431.80K.
This is 423.39% and $349.30K more than what they got when they sold the stock.

Insider Trading

See recent insider trades of Barry Caldwell.

STAA

13,000 shares

STAA

Jun 9, 2014

Received

STAA

47,000 shares

STAA

Mar 7, 2014

Received

STAA

15,000 shares

STAA

Mar 4, 2013

Received

STAA

$25.20K

STAA at $5.04/share

Nov 14, 2012

Purchase

STAA

$32.83K

STAA at $6.57/share

Aug 9, 2012

Purchase

STAA

$44.28K

STAA at $8.86/share

May 29, 2012

Purchase

STAA

$44.28K

STAA at $8.86/share

May 29, 2012

Received

STAA

15,000 shares

STAA

Mar 2, 2012

Received

STAA

$80.50K

STAA at $8.05/share

Aug 26, 2011

Sale

STAA

15,000 shares

STAA

Mar 15, 2011

Received

Compensation History

See how much did Barry Caldwell make over time.

Barry Caldwell's compensation varied throughout his time at Staar Surgical, ranging from a total of about $437,932 in 2005 to a high of around $546,838 in 2014. Notably, in 2015, his last year as CEO, he received around $396,783, driven by his consulting fees following retirement rather than traditional performance metrics. His package included a mix of salary, bonuses, and stock options, ensuring that his rewards were tied to both individual and company performance. The remuneration strategy at Staar was designed to align executive compensation with long-term shareholder value, indicating that Caldwell’s pay was reflective of the company's challenges and victories during his leadership. This approach to compensation highlights a career focused not just on immediate gains but on fostering sustainable growth and innovation at Staar Surgical.

Year

2015

Total Compensation

$498.93K

Salary

$88.62K

Board Justification

The compensation philosophy aims to align executive compensation with company performance and market competitiveness, although specific details for Mr. Caldwell's compensation were not detailed due to his retirement.

Bonus

$0.00

Board Justification

Mr. Caldwell did not participate in the 2015 Incentive Bonus Plan as he retired in March 2015.

Other

$308.17K

Board Justification

Includes consulting fees of $277,333 and COBRA premium reimbursements of $23,933 paid during the consulting period following retirement.

Restricted Stock

$102.15K(15K common stock)

Board Justification

15,000 shares of stock vested in 2015 as part of his retirement agreement.

Performance Metrics

Mr. Caldwell was not eligible for performance metrics in 2015 due to his retirement.

Other Staar Surgical CEOs

Here are other CEOs of Staar Surgical

David Bailey

Ex-CEO of Staar Surgical

April 2007 - October 2007

Caren Mason

CEO of Staar Surgical

March 2015 - Present